SCNX Q3'26 Earnings: revenue estimate is 1.22M USD

Scienture Holdings (SCNX) will report Q3'26 earnings on November 12. Analysts expect revenue of 1.22M USD and an EPS of (1.57) USD. Details are available on the company's financials page.

Original reporting
Published Nov 5, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SCNX Q3'26 Earnings: revenue estimate is 1.22M USD — source image
Decision brief

The 30-second read

$SCNXNeutralLow
01

Why it matters

The earnings preview provides the first disclosed guidance for Q3'26, offering a baseline for traders.

02

Market read

New earnings guidance for a micro‑cap; limited but actionable for niche traders.

03

What to watch

Potential hidden contracts or upcoming product launches not disclosed in the preview.

Relevance 6/10Novelty 6/10Timing: pre‑market on Nov 12

Background

SCNX (Scienture Holdings, Inc.) is a low‑cap company with limited public coverage.

Company-level read

Ticker impact

$SCNXNeutralMedium confidence
Context

SCNX will announce Q3'26 earnings on Nov 12 with revenue estimate of $1.22M and EPS of -$1.57.

Expected impact

likely modest pressure if results miss expectations; limited upside on a beat.

Evidence & confidence

Small absolute numbers and negative earnings reduce material impact; market may react modestly.

Market effects

Minimal effect on the broader sector; only relevant to niche investors in micro‑caps.

No significant regional impact.

Negligible.

Counterpoint

If the company surprises with a revenue beat, a short squeeze could briefly lift the stock.

Key entities

  • Scienture Holdings, Inc.

    Issuer of the earnings preview.

Related articles

$SCNXMed

Scienture Holdings, Inc. (SCNX): Continued Arbli™ sales growth, combined with REZENOPY™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential…

Scienture Holdings, Inc. (SCNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Continued Arbli ™ sales growth, combined with REZENOPY ™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential revenue growth Arbli ™ wholesale unit sales increased 74% sequentially, with recent institutional formulary additi

$SCNXMed

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

Scienture Holdings, Inc. (SCNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company’s Growing Commercial Revenue Base Q2 2026 Operat

$SCNXMedAI 8/10

Scienture Holdings, Inc.: SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

Scienture Holdings (NASDAQ: SCNX) reported Q2 2026 results: revenue rose about 510% sequentially to $343,639 from $56,325 in Q1. Q2 gross margin was about 97.7%. Operating loss improved about 48% to ~$2.7M and net loss narrowed about 58% to ~$2.8M. The company began commercial launch of REZENOPY and cited USPTO patent grants and expanded payer coverage.

$SCNXMedAI 8/10

SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product

Scienture (NASDAQ:SCNX) says it has commercially launched REZENOPY, a 10 mg naloxone hydrochloride nasal spray, after fulfilling initial U.S. wholesaler purchase orders and starting nationwide distribution. The company cites IQVIA data for a $143 million U.S. naloxone market (9.8 million units) and says payer coverage could exceed 100 million lives via GPO access to 5,000+ facilities. No revenue guidance was provided.

$SCNXMed

Scienture Announces Commercial Inventory Readiness For REZENOPY Naloxone Nasal Spray; Stock Up

Scienture Holdings (SCNX) said it completed manufacturing commercial launch inventory for REZENOPY naloxone nasal spray 10 mg and will start shipments to U.S. wholesalers in July, with broad availability expected in August. The company cited IQVIA data valuing the U.S. naloxone market at about $144 million annually and said payer access could cover over 100 million lives.